Atea Pharmaceuticals, INC Form 4 insider transactions

Atea Pharmaceuticals director Polly A. Murphy filed an amendment to correct the transaction date of a recent open-market share purchase.

Polly Murphy, a Director at Atea Pharmaceuticals, Inc., reported the acquisition of 6,100 shares of common stock.

Atea Pharmaceuticals' Chief Financial Officer, Andrea Corcoran, exercised stock options to acquire 60,000 shares of common stock at $1.24 per share.

Atea Pharmaceuticals' Chief Medical Officer, Maria Arantxa Horga, increased her direct ownership of common stock and acquired new stock options following RSU vesting.

Atea Pharmaceuticals' Chief Commercial Officer, John Vavricka, reported significant equity transactions including RSU vesting, stock option grants, and common stock sales for tax purposes.

Atea Pharmaceuticals' Chief Development Officer, Janet Hammond, increased her direct beneficial ownership of common stock and acquired new stock options following RSU vesting and tax-related dispositions.

Atea Pharmaceuticals' CFO Andrea Corcoran reported the vesting of restricted stock units and the grant of new stock options, alongside a tax-related sale of shares.

Atea Pharmaceuticals' President, CEO, and Chairman, Jean-Pierre Sommadossi, increased his direct beneficial ownership through RSU vesting and stock option exercise.

Atea Pharmaceuticals' EVP and Chief Accounting Officer, Wayne Foster, reported the acquisition of common stock through RSU vesting and a new stock option grant.

Atea Pharmaceuticals, Inc. Director Polly A. Murphy reported the acquisition of common stock through RSU conversion and new grants of restricted stock units and stock options, aligning her interests with shareholders.

Atea Pharmaceuticals, Inc. Director Franklin M. Berger reported the acquisition of 29,600 shares of common stock through RSU vesting, alongside new grants of 29,600 restricted stock units and 41,200 stock options.

Atea Pharmaceuticals, Inc. Director Barbara Gayle Duncan reported an increase in her beneficial ownership of common stock and received new equity grants, including restricted stock units and stock options.

Atea Pharmaceuticals, Inc. Director Bruce Polsky reported the acquisition of 29,600 shares of common stock through RSU conversion and new grants of 29,600 restricted stock units and 41,200 stock options.

Atea Pharmaceuticals, Inc. Director Jerome M. Adams reported the vesting of 29,600 Restricted Stock Units into common stock and received new grants of 29,600 RSUs and 41,200 stock options.

Atea Pharmaceuticals, Inc. Director Bruno Lucidi reported the vesting of 29,600 restricted stock units into common stock and the grant of new restricted stock units and stock options, increasing his beneficial ownership.

Atea Pharmaceuticals, Inc. Director Howard Berman was granted 164,800 stock options with an exercise price of $3.25, vesting over three years.

Director Arthur S. Kirsch of Atea Pharmaceuticals acquired stock options on February 20, 2025.

Janet Hammond, Chief Development Officer of Atea Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.

John Vavricka, Chief Commercial Officer of Atea Pharmaceuticals, reports transactions involving restricted stock units, performance stock units, and stock options.

Maria Arantxa Horga, Chief Medical Officer of Atea Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities.

Andrea Corcoran, CFO of Atea Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.

Jean-Pierre Sommadossi, President, CEO, and Chairman of Atea Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities.

Wayne Foster, EVP and Chief Accounting Officer of Atea Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Atea Pharmaceuticals director Franklin M. Berger amended a previous filing to correct a transaction code error, confirming the acquisition of 25,000 shares of common stock.

Director Franklin M. Berger of Atea Pharmaceuticals, Inc. has acquired 25,000 shares of common stock in multiple transactions over two days.

Atea Pharmaceuticals director Franklin M. Berger sold 359,606 shares of common stock at an average price of $2.8461 per share on December 10, 2024.

Jean-Pierre Sommadossi, CEO of Atea Pharmaceuticals, sold shares of common stock over three days in September 2024 under a pre-arranged Rule 10b5-1 trading plan.

Director Barbara Gayle Duncan reported acquiring stock options and restricted stock units in Atea Pharmaceuticals, Inc. on June 21, 2024.

Director Franklin M. Berger reports acquiring stock options and restricted stock units in Atea Pharmaceuticals.

Director Jerome M. Adams reports acquisition of restricted stock units and stock options in Atea Pharmaceuticals.